🫀 Semaglutide vs Tirzepatide: Early CV Benefits in Overweight/Obese Patients with ASCVD

🔥 Main in 3 points

• In a real-world US cohort, semaglutide was associated with a 29% lower risk of major adverse CV events (MACE) than tirzepatide in patients with overweight/obesity and known ASCVD; benefit was statistically significant.
• Per-protocol analysis (adherent patients) showed even greater risk reductions—57% lower for 3-point MACE.
• These benefits were observed in non-diabetic patients, expanding semaglutide's real-world evidence base.

🧪 Context

Propensity-matched, retrospective cohort (Komodo database, US): 10,625 semaglutide vs 10,625 tirzepatide first-time users (≥45 years, overweight/obesity + established ASCVD, no diabetes), May 2022–Jan 2025. Outcomes: 3-point and 5-point MACE (MI, stroke, CV death, revascularization, HF hospitalization).

📍 Practical significance

• For high-risk patients with obesity and ASCVD but without diabetes, semaglutide demonstrates earlier, greater CV protection than tirzepatide.
• Prioritize semaglutide when rapid CV benefit is a key goal.
• Reinforces a proactive approach to CV risk reduction using GLP-1RA in non-diabetic ASCVD.

🔗 PubMed | DOI

🫀 Oral Semaglutide Reduces Mortality in HFpEF with Type 2 Diabetes

✅ Study answer

• Oral semaglutide was associated with a 39% reduction in 1-year risk of all-cause death (HR 0.61, 95% CI 0.50–0.75) vs sitagliptin in real-world HFpEF+T2D patients.
• Hospitalization was also lower (37.1% vs 42.4%; HR 0.83, 95% CI 0.77–0.90).

📍 How to apply

• Consider oral semaglutide as a preferred option for T2D patients with concomitant HFpEF—both for glycemic and survival benefits.
• Monitor for tolerability, adjusting therapy as per standard protocol.

🔗 PubMed | DOI

📈 Semaglutide Superior to Dulaglutide for CV Outcomes in T2D with ASCVD

🔄 Real-world CV outcome comparison

🧪 What was studied

Retrospective analysis (Optum CDM, US) of 75,243 T2D+ASCVD patients initiating once-weekly semaglutide (n=42,007) vs dulaglutide (n=33,236), 2018–2024.

📊 Key results

• Semaglutide: 3-point MACE incidence rate 25.7/1000 person-years
• Dulaglutide: 33.0/1000 person-years
• Hazard ratio for semaglutide vs dulaglutide: 0.78 (95% CI 0.70–0.87; p <0.001), i.e., 22% lower CV risk with semaglutide.

📍 What this changes in practice

• For T2D+ASCVD patients, semaglutide may confer superior CV protection compared to dulaglutide.
• Practical for real-world US patient profiles; integrate this data in GLP-1RA selection.

🔗 PubMed | DOI

🧾 Practical Considerations: Oral Semaglutide Discontinuation Due to GI AEs

🧐 When starting oral semaglutide in Japanese adults with T2D

✅ Do

• Evaluate baseline HbA1c—higher HbA1c predicts early discontinuation at 3 mg dose.
• Carefully consider concurrent metformin; assess metformin dose.

⚠️ With caution

• High-dose metformin (≥1000 mg/day) increases GI adverse event–driven discontinuation risk at 3 mg.
• Monitor early GI symptoms, especially during dose escalation.

🚫 Avoid

• Ignoring GI complaints in the first weeks, especially for patients already on metformin.

🔗 PubMed | DOI

🫀 GLP-1RAs in PAD: Reduced Amputation and Improved Walking Distance (Semaglutide & Liraglutide Data Included)

🔥 Main in 3 points

• Meta-analysis shows semaglutide and liraglutide improve walking distance and reduce lower extremity amputation risk in T2D+PAD.
• 55% and 54% risk reduction in amputation for tirzepatide and semaglutide, respectively, in cohort studies.
• Benefit on amputation risk was not observed in patients with pre-existing diabetic foot ulcers.

🧪 Context

7 studies (RCT + cohort, 107,092 pts); primary outcomes: walking distance, major adverse limb events (MALE), lower extremity amputation.

📍 Practical significance

• GLP-1RA (esp. semaglutide) should be considered in T2D+PAD for limb and functional benefits.
• For advanced foot disease, risk reduction may not be as robust—individualize therapy.

🔗 PubMed | DOI

⚠️ Safety Signal: Dermatologic AEs with Semaglutide (and Peers), but Less than DPP-4 Inhibitors

🧪 Context

FAERS analysis (2018–2024) of GLP-1RA (including semaglutide): Cutaneous adverse events ("rash", "pruritus", "urticaria", "alopecia", "angioedema"); DPP-4 inhibitors as comparator.

📊 Numbers

• Up to 8.16% of GLP-1RA cases had dermatologic AEs; semaglutide: highest rate, but OR <1 relative to DPP-4 inhibitors.
• Mean patient age: 60; more frequent in females.

📍 Actions

• Counsel patients on low—but real—risk for rash, urticaria, pruritus.
• Reassure: overall lower risk compared to DPP-4 inhibitors.
• Remain vigilant in the setting of new dermatologic symptoms, especially with semaglutide.

🔗 PubMed | DOI

🧠 Semaglutide Reduces Alzheimer’s Disease Biomarkers but Not Cognitive Endpoints

🧠 Emerging Potential in Neurodegenerative Disease

🧪 What was studied

Review: Preclinical and human evidence of semaglutide in neurodegenerative disorders—esp. Alzheimer’s disease (AD), with focus on neuroinflammatory pathways and human CSF biomarkers.

📈 Key results

• Rapid reductions in CSF p-tau, t-tau, neurogranin, and YKL-40 (neuroinflammation) in AD,
• Favorable modulation of inflammatory T-cell phenotype.
• However, Phase 3 trials failed to improve primary cognitive outcomes (CDR-SB).

📍 What this changes in practice

• Semaglutide’s anti-neuroinflammatory effect is a plausible future disease-modifying strategy—especially for AD/MCI, MS, ALS, HD, LBD.
• Clinical translation and rigorous trials are still required before adoption.

🔗 PubMed | DOI